Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 395 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IV Prostate Cancer AJCC v7 Clear all
Not listed Phase 2 Interventional

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

NCT00024414
View directory record Official record
Conditions
Prostate Cancer
Interventions
DHA-paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
8
States / cities
Tucson, Arizona • Berkeley, California • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

NCT00096499
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ispinesib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00589420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, sorafenib tosylate
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional

Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer

NCT00084526
View directory record Official record
Conditions
Prostate Cancer
Interventions
computed tomography, ultrasound imaging
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

NCT01385059
View directory record Official record
Conditions
Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
axitinib, therapeutic conventional surgery, enzyme-linked immunosorbent assay, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

NCT01812668
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
cabozantinib-s-malate, fluorine F 18 d-FMAU, positron emission tomography, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

NCT00002889
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin, leuprolide acetate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
30 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

NCT03360721
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

NCT02206334
View directory record Official record
Conditions
Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 3, 2026, 9:50 AM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 3, 2026, 9:50 AM EDT
Not listed Phase 1Phase 2 Interventional

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00002775
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00118092
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
tanespimycin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

NCT03503344
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Apalutamide, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 3, 2026, 9:50 AM EDT
Active, not recruiting Phase 2 Interventional

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT03344211
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride
Drug · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

NCT01912820
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
green tea extract, quercetin, placebo, therapeutic conventional surgery, laboratory biomarker analysis
Dietary Supplement · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

NCT00634582
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00937768
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

NCT02048150
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
anti-PSMA monoclonal antibody MDX1201-A488, robot-assisted laparoscopic surgery, diffuse optical imaging, pharmacological study, Laboratory Biomarker, Questionnaire
Biological · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
36 Years to 74 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 3, 2026, 9:50 AM EDT
Recruiting Phase 1 Interventional

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

NCT05398302
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Image Guided Biopsy
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003516
View directory record Official record
Conditions
Prostate Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Not applicable Interventional

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

NCT03368547
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

NCT00400517
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, thalidomide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 120 Years · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 3, 2026, 9:50 AM EDT